Toripalimab Plus Gemcitabine/Cisplatin Shown Improved Survival in Recurrent/Metastatic Nasopharyngeal Carcinoma
According to a randomized trial, "Adding the investigational PD-1 immune checkpoint inhibitor toripalimab to standard frontline chemotherapy significantly helps in order to delay the disease progression in patients with the recurrent/metastatic nasopharyngeal carcinoma. Outcomes from the phase-III JUPITER-2 trial demonstrated that the addition of toripalimab significantly improved the progression-free survival (PFS) in comparison to placebo, with a median 11.7 months in comparison to 8.0 months (HR 0.52, 95 percent CI 0.36 to 0.74, P=0.0003), reported Rui-Hua Xu, MD, Ph.D., of the Sun Yat-Sen University Cancer Center in Guangzhou in China. Speaking at a press briefing in advance of the virtual American Society of Clinical Oncology (ASCO) annual meeting, Xu said, "In an interim analysis of overall survival (OS), toripalimab plus gemcitabine / cisplatin also demonstrated benefit over placebo." "The combination was safe, and no new safety signals were noted," he...